An interventional study of Royal Jelly and Placebo in Hypertension, Cardiovascular Diseases (CVD) and Inflammation, sponsored by Universidade Federal Fluminense. Recruiting at 1 site in Brazil. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-05-19.
Sponsored by Universidade Federal Fluminense · Not applicable, Interventional, and Health services research
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 209 studies in Hypertension with a site in Brazil — 28 open to participants now, 33 under way, 6 of them phase 3. Hypertension · Brazil.
Among the 209 studies in Hypertension with a site in Brazil, this one is the 151st largest by planned enrollment of the 189 interventional ones that give a count, is one of 12 that started in 2024, is one of 112 with no phase, reaches primary completion later than 10 of the 32 other live ones, and was the 192nd registered.
6,128 studies on the registry are indexed under Hypertension; 907 are open to participants now.
Browse Hypertension studies →28 of the 209 studies in Hypertension with a site in Brazil are open now. Recruiting first, the newest first:
University of Nove de Julho · Sites in Brazil
Ages 18–65
AstraZeneca · Sites in Brazil
Ages 18+
Instituto Dante Pazzanese de Cardiologia · Sites in Brazil
Ages 18+
Raphael Mendes Ritti Dias · Sites in Brazil
Ages 60+
Universidade Federal Fluminense · Sites in Brazil
Ages 18–75
A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →
Of the 552 Hypertension studies recruiting now, 260 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 136 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
209 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 7 · Phase 3 40 · Phase 4 31
First in 1999; this study’s year is marked. 12 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 34 is below the median of 100 across 4,585 interventional studies indexed under Hypertension.
Median enrollment 80 across the 189 interventional studies, 127 across the 18 observational. Of the 136 that completed or were terminated, 20 (15%) have results posted.
This tab as a report to print or save as PDF → With an account.
37 of 209 have an industry lead sponsor. The 10 most frequent:
Universidade Federal Fluminense is the lead sponsor of 72 studies on the registry; 13 are open to participants now.
Universidade Federal Fluminense has 4 studies filed under Hypertension — fewer than ten, so there is no comparison to draw.
18 of the studies in Hypertension with a site in Brazil that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03683186Phase 3United TherapeuticsA Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension | 2026-12 |
| NCT07361276AstraZenecaObservational Study That Will Evaluate Treatment Patterns in the Management of Hypertension in the Public Primary Care System | 2026-11-30 |
| NCT06105775University of Sao PauloInorganic Nitrate Supplementation in Chronic Hypertensive Pregnancies | 2026-12 |
| NCT06169241National Institute of Cardiology, Laranjeiras, BrazilEffect of Nitrate Supplementation on Blood Pressure and Microvascular Function of Resistant Hypertensive Patients | 2026-12 |
| NCT06917131Universidade Federal FluminenseRoyal Jelly as a Strategy to Modulate Inflammation and Oxidative Stress in Patients With Systemic Arterial Hypertension | 2026-12-10 |
Add all 18 to your calendar (.ics) → With an account.
Among the 209 studies in Hypertension with a site in Brazil, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The study aims to evaluate the effect of the royal jelly on inflammation and oxidative stress in participants with systemic arterial hypertension. A longitudinal double-blind randomized clinical trial will be carried out, involving hypertensive participants for two months.
Royal jelly (RG) is considered a superfood that has been used in traditional medicine and dietary supplementation due to its antioxidant, anti-inflammatory, immunomodulatory, and regenerative properties. The antioxidant and anti-inflammatory effects of GR highlight its potential as a natural supplement for the prevention and management of several health conditions. Although in vitro and animal model data are promising, clinical studies are still needed to validate the effects of royal jelly in human populations.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive 2 capsules per day, providing the dosage of 300mg of royal jelly for 2 months (8 weeks).
Dietary Supplement: Royal Jelly
The placebo group will receive 2 capsules per day (containing microcrystalline cellulose and magnesium stearate in colored gelatin capsules capable of masking the appearance of the internal content), at the same time for 2 months.
Dietary Supplement: Placebo
Participants will receive 2 capsules per day, providing the dosage of 300mg of royal jelly for 2 months (8 weeks).
The placebo group will receive 2 capsules per day (containing microcrystalline cellulose and magnesium stearate in colored gelatin capsules capable of masking the appearance of the internal content), at the same time for 2 months.
Change of inflammatory transcripton factor
Assessment of NFkB expression levels in blood samples collected at baseline and after 8 weeks of supplementation.
Time frame: Baseline and 8 weeks
Change in interleukin-6 (IL-6) levels
Assessment of changes in serum interleukin-6 (IL-6) levels after supplementation.
Time frame: Baseline and 8 weeks
Change in tumor necrosis factor-alpha (TNF-α) levels
Assessment of changes in serum tumor necrosis factor-alpha (TNF-α) levels after supplementation.
Time frame: Baseline and 8 weeks
Change in Nrf2 expression
Assessment of changes in Nrf2 expression after supplementation.
Time frame: Baseline and 8 weeks
Change in C-reactive protein (CRP) levels
Assessment of changes in serum C-reactive protein (CRP) levels after supplementation.
Time frame: Baseline and 8 weeks
Change in antioxidant enzyme activity
Assessment of changes in antioxidant enzyme activity after supplementation.
Time frame: Baseline and 8 weeks
Plan to share: No — Participant data will not be public to other research unless necessary.
No publications or documents are linked to this record.
Started Sep 2024 (actual). Primary completion is estimated for Dec 2026, 26 months after the start.
Of 1,407 non-industry interventional studies with no phase under Hypertension, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 26 months is above that.
Counting every sponsor, half of 1,502 studies reached it within 23 months; a quarter within 10 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Royal Jelly
Universidade Federal Fluminense